)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals (ARWR) investor relations material
Arrowhead Pharmaceuticals H.C. Wainwright 28th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 28th Annual Global Investment Conference summary16 Sep, 2026
Platform and pipeline overview
Developed a broad RNAi platform targeting multiple cell types, with five represented in clinical candidates.
Transitioned to a commercial stage with 21–22 drug candidates in clinical studies.
Plans to access a new cell type every 18–24 months, expanding beyond liver to CNS and other tissues.
Focused on building a broad-based company addressing diverse indications.
REDEMPLO (plozasiran) launch and expansion
REDEMPLO approved for FCS, targeting both genetic and clinically defined FCS populations.
Contracting with payers established; sales force expanded to address larger clinical FCS population.
Preparing for SHTG launch in Q2 2027, with further sales force growth planned in early 2027.
SHASTA-3 and SHASTA-4 trial results
Achieved ~80% reduction in triglycerides in severe hypertriglyceridemia patients.
Statistically significant reduction in acute pancreatitis risk, with 78–100% risk reduction in high-risk subgroups.
Clean safety profile: no significant liver, hypersensitivity, or thrombocytopenia issues; no increase in liver fat.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Arrowhead Pharmaceuticals
- Breakthrough dual gene knockdown, robust triglyceride therapy, and pipeline innovation drive growth.ARWR
Morgan Stanley 24th Annual Global Healthcare Conference - Strong efficacy, safety, and launch readiness position plozasiran for high-impact SHTG entry.ARWR12th Annual Cantor Fitzgerald Global Healthcare Conference
- Plozasiran delivers robust, sustained efficacy and safety for high-risk SHTG patients.ARWRKOL event
- SHASTA-3/4 trials drove strong efficacy, revenue growth, and global REDEMPLO expansion.ARWRQ3 2026
- Plozasiran nears launch after robust phase III data, with lung program readouts expected soon.ARWRChardan's 8th Annual Genetic Medicines Conference
- ARO-INHBE plus tirzepatide doubled weight loss and tripled fat reduction in obese diabetics.ARWRStudy Update
- FDA approval, record revenue, and global licensing deals mark a pivotal commercial milestone.ARWRQ4 2025
- FDA approved Redemplo after Phase 3 data showed 80% triglyceride reduction in FCS patients.ARWRStudy Result
- Q2 FY2025 saw $542.7M revenue, $370.4M net income, and funding secured into 2028.ARWRQ2 2025
Next Arrowhead Pharmaceuticals earnings date
Q4 202625 Nov, 2026
Arrowhead Pharmaceuticals
Next Arrowhead Pharmaceuticals earnings date
Q4 202625 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage